These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 32330776)

  • 21. The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
    Liu Y; Wang S; Xiang LH; Xu G; Dong L; Sun Y; Ye B; Zhang Y; Xu H
    Br J Radiol; 2022 Sep; 95(1138):20220209. PubMed ID: 35877385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of relationships between the final Gleason score, PI-RADS v2 score, ADC value, PSA level, and tumor diameter in patients that underwent radical prostatectomy due to prostate cancer.
    Gündoğdu E; Emekli E; Kebapçı M
    Radiol Med; 2020 Sep; 125(9):827-837. PubMed ID: 32266690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-related characteristics predict prostate cancers in men with PI-RADS 4-5 to further optimize the diagnostic performance of MRI.
    Xiang L; Ma S; Xu Y; Jiang L; Guo H; Liu H; Liu Y
    Abdom Radiol (NY); 2023 Dec; 48(12):3766-3773. PubMed ID: 37776336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The roles of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer.
    Zheng S; Jiang S; Chen Z; Huang Z; Shi W; Liu B; Xu Y; Guo Y; Yang H; Li M
    PLoS One; 2019; 14(11):e0218645. PubMed ID: 31743339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Performance of PI-RADS v2, Proposed Adjusted PI-RADS v2 and Biparametric Magnetic Resonance Imaging for Prostate Cancer Detection: A Preliminary Study.
    Cai GH; Yang QH; Chen WB; Liu QY; Zeng YR; Zeng YJ
    Curr Oncol; 2021 May; 28(3):1823-1834. PubMed ID: 34065851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lesion volume predicts prostate cancer risk and aggressiveness: validation of its value alone and matched with prostate imaging reporting and data system score.
    Martorana E; Pirola GM; Scialpi M; Micali S; Iseppi A; Bonetti LR; Kaleci S; Torricelli P; Bianchi G
    BJU Int; 2017 Jul; 120(1):92-103. PubMed ID: 27608292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The combination of prostate imaging reporting and data system version 2 (PI-RADS v2) and periprostatic fat thickness on multi-parametric MRI to predict the presence of prostate cancer.
    Cao Y; Cao M; Chen Y; Yu W; Fan Y; Liu Q; Gao G; Zhao Z; Wang X; Jin J
    Oncotarget; 2017 Jul; 8(27):44040-44049. PubMed ID: 28476042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer.
    Zhang Y; Zeng N; Zhu YC; Huang YXR; Guo Q; Tian Y
    World J Surg Oncol; 2018 Jun; 16(1):102. PubMed ID: 29859119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PSA-density does not improve bi-parametric prostate MR detection of prostate cancer in a biopsy naïve patient population.
    Cuocolo R; Stanzione A; Rusconi G; Petretta M; Ponsiglione A; Fusco F; Longo N; Persico F; Cocozza S; Brunetti A; Imbriaco M
    Eur J Radiol; 2018 Jul; 104():64-70. PubMed ID: 29857868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers.
    Wei CG; Zhang YY; Pan P; Chen T; Yu HC; Dai GC; Tu J; Yang S; Zhao WL; Shen JK
    AJR Am J Roentgenol; 2021 May; 216(5):1247-1256. PubMed ID: 32755220
    [No Abstract]   [Full Text] [Related]  

  • 31. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
    Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
    Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Head-to-head comparison of PI-RADS v2 and PI-RADS v1.
    Polanec S; Helbich TH; Bickel H; Pinker-Domenig K; Georg D; Shariat SF; Aulitzky W; Susani M; Baltzer PA
    Eur J Radiol; 2016 Jun; 85(6):1125-31. PubMed ID: 27161062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
    Wei X; Xu J; Zhong S; Zou J; Cheng Z; Ding Z; Zhou X
    Abdom Radiol (NY); 2022 Oct; 47(10):3574-3582. PubMed ID: 35788882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The clinical decision-making value of prostate specific antigen and its derived indicators in prostate imaging reporting and data system version 2 3 lesions].
    Yang S; Zhang YY; Zhao WL; Wei CG; Chen T; Li MJ; Tan SX; Shen JK
    Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(13):997-1001. PubMed ID: 32294856
    [No Abstract]   [Full Text] [Related]  

  • 35. Exploration of the diagnostic capacity of PSAMR combined with PI-RADS scoring for clinically significant prostate cancer and establishment and validation of the Nomogram prediction model.
    Li D; Zhang L; Xu Y; Wu X; Hua S; Jiang Y; Huang Q; Gao Y
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11309-11317. PubMed ID: 37365430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can high b-value 3.0 T biparametric MRI with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) be used in biopsy-naïve men?
    Wang G; Yu G; Chen J; Yang G; Xu H; Chen Z; Wang G; Bai Z
    Clin Imaging; 2022 Aug; 88():80-86. PubMed ID: 34243992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinico-radiological characteristic-based machine learning in reducing unnecessary prostate biopsies of PI-RADS 3 lesions with dual validation.
    Kan Y; Zhang Q; Hao J; Wang W; Zhuang J; Gao J; Huang H; Liang J; Marra G; Calleris G; Oderda M; Zhao X; Gontero P; Guo H
    Eur Radiol; 2020 Nov; 30(11):6274-6284. PubMed ID: 32524222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRI-Based Radiomics Nomogram for Predicting Prostate Cancer with Gray-Zone Prostate-Specific Antigen Levels to Reduce Unnecessary Biopsies.
    Zhang L; Zhang J; Tang M; Lei XY; Li LC
    Diagnostics (Basel); 2022 Dec; 12(12):. PubMed ID: 36553012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies.
    Wang Y; Wang L; Tang X; Zhang Y; Zhang N; Zhi B; Niu X
    BMC Med Imaging; 2023 Aug; 23(1):106. PubMed ID: 37582697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2.
    Chen T; Li M; Gu Y; Zhang Y; Yang S; Wei C; Wu J; Li X; Zhao W; Shen J
    J Magn Reson Imaging; 2019 Mar; 49(3):875-884. PubMed ID: 30230108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.